Shire PLC – Company Overview
 |
|
| Company | Shire PLC |
| Corporate Headquarters | 5 Riverwalk, Citywest Business Campus, Dublin, Ireland |
| CEO | Flemming Ornskov |
| CFO | Jeff Poulton |
| Industry | Pharmaceuticals |
| Type | Public |
| Founders | Dr James Murray, Dennis Stephens, Peter Moriarty, and Geoff Hall |
| Founded | 1986 |
| Stock symbol | NASDAQ:SHPG, LSE:SHP |
| Revenues | $6,416.7 million USD (2015) |
| Operating expenses | $4,997.2 million USD (2015) |
| Net income | $1,303.4 million USD (2015) |
| Employees | 5,548 (2015) |
| Website | https://www.shire.com/ |
| Corporate contact number | +353 1 429 7700 |
| IR contact number | +1 781 482 0945 |
| IR email address | [email protected] |
Shire PLC is a specialty biopharmaceutical company, headquartered in Dublin, Ireland. The company’s vision is “to transform the lives of people around the world whose health is impacted by rare and other specialized conditions, through providing innovative treatments.”
It focuses on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine.
It has a broad portfolio of pharmaceuticals, including Adderall XR, Vyvanse, Intuniv, Fosrenol, Replagal, Pentasa, VPRIV, Elaprase, Firazyr, Lialda, and Dermagraft.
Shire plc was founded in 1986 by Harry Stratford, Dr James Murray, Dennis Stephens, Peter Moriarty, and Geoff Hall. Its initial products were calcium supplements to help prevent and treat osteoporosis.
It has approximately 5,000 employees in more than 29 countries, with a major operation base in Basingstoke, Hampshire, England, in addition to major offices in Wayne, Pennsylvania and Cambridge, Massachusetts.
The company is publicly listed on the London Stock Exchange (LSE: SHP), and has a secondary listing on the NASDAQ Stock Market (NYSE: SHPG).
Shire PLC – Financial Results
| Key figures (in millions of USD) | 2015* | 2014* |
| Revenues | $6,416.7 | $6,022.1 |
| Operating expenses | $4,997.2 | $4,324.1 |
| Net income | $1,303.4 | $3,405.5 |
| Total assets | $16,609.8 | $13,632.1 |
| Cash and cash equivalents at beginning of period | $2,982.4 | $2,239.4 |
| Cash and cash equivalents at end of period | $135.5 | $2,982.4 |
*For the years ended December 31, 2015 and 2014
Source: “Shire PLC. – 2015 Annual Report”
News about Shire PLC reported by our Market Business News team
January 11, 2015: Shire to buy NPS Pharma for $5.2 billion at $46 per share